| IL8-CXCR2 pathway inhibition as a therapeutic strategy against MDS and AML stem cells C Schinke, O Giricz, W Li, A Shastri, S Gordon, L Barreyro, T Bhagat, ... Blood, The Journal of the American Society of Hematology 125 (20), 3144-3152, 2015 | 179 | 2015 |
| Stem and progenitor cell alterations in myelodysplastic syndromes A Shastri, B Will, U Steidl, A Verma Blood, The Journal of the American Society of Hematology 129 (12), 1586-1594, 2017 | 120 | 2017 |
| Thrombolysis for acute ischemic stroke in patients with cancer: a population study SB Murthy, S Karanth, S Shah, A Shastri, CPV Rao, EM Bershad, ... Stroke 44 (12), 3573-3576, 2013 | 99 | 2013 |
| Delayed clearance of SARS-CoV2 in male compared to female patients: high ACE2 expression in testes suggests possible existence of gender-specific viral reservoirs A Shastri, J Wheat, S Agrawal, N Chaterjee, K Pradhan, M Goldfinger, ... MedRxiv, 2020.04. 16.20060566, 2020 | 88 | 2020 |
| Antisense STAT3 inhibitor decreases viability of myelodysplastic and leukemic stem cells A Shastri, G Choudhary, M Teixeira, S Gordon-Mitchell, N Ramachandra, ... The Journal of clinical investigation 128 (12), 5479-5488, 2018 | 76 | 2018 |
| The SILK flow diverter in the treatment of intracranial aneurysms SB Murthy, S Shah, A Shastri, CPV Rao, EM Bershad, JI Suarez Journal of Clinical Neuroscience 21 (2), 203-206, 2014 | 76 | 2014 |
| North American ATLL has a distinct mutational and transcriptional profile and responds to epigenetic therapies UA Shah, EY Chung, O Giricz, K Pradhan, K Kataoka, S Gordon-Mitchell, ... Blood, The Journal of the American Society of Hematology 132 (14), 1507-1518, 2018 | 73 | 2018 |
| Pharmacokinetic exposure equivalence and preliminary efficacy and safety from a randomized cross over phase 3 study (ASCERTAIN study) of an oral hypomethylating agent ASTX727 … G Garcia-Manero, J McCloskey, EA Griffiths, KWL Yee, AM Zeidan, ... Blood 134, 846, 2019 | 72 | 2019 |
| Axicabtagene ciloleucel CD19 CAR-T cell therapy results in high rates of systemic and neurologic remissions in ten patients with refractory large B cell lymphoma including two … A Abbasi, S Peeke, N Shah, J Mustafa, F Khatun, A Lombardo, M Abreu, ... Journal of hematology & oncology 13, 1-4, 2020 | 69 | 2020 |
| Thrombopoietin receptor–independent stimulation of hematopoietic stem cells by eltrombopag YR Kao, J Chen, SR Narayanagari, TI Todorova, MM Aivalioti, M Ferreira, ... Science translational medicine 10 (458), eaas9563, 2018 | 64 | 2018 |
| Pexmetinib: a novel dual inhibitor of Tie2 and p38 MAPK with efficacy in preclinical models of myelodysplastic syndromes and acute myeloid leukemia L Bachegowda, K Morrone, SL Winski, I Mantzaris, M Bartenstein, ... Cancer research 76 (16), 4841-4849, 2016 | 42 | 2016 |
| ASXL1 mutations are associated with distinct epigenomic alterations that lead to sensitivity to venetoclax and azacytidine NE Rahmani, N Ramachandra, S Sahu, N Gitego, A Lopez, K Pradhan, ... Blood cancer journal 11 (9), 157, 2021 | 40 | 2021 |
| Phase II study of pomalidomide in combination with prednisone in patients with myelofibrosis and significant anemia N Daver, A Shastri, T Kadia, K Newberry, N Pemmaraju, E Jabbour, ... Leukemia research 38 (9), 1126-1129, 2014 | 38 | 2014 |
| Adult T-cell leukemia/lymphoma in the Caribbean cohort is a distinct clinical entity with dismal response to conventional chemotherapy M Zell, A Assal, O Derman, N Kornblum, R Battini, Y Wang, ... Oncotarget 7 (32), 51981, 2016 | 36 | 2016 |
| High prevalence and allele burden-independent prognostic importance of p53 mutations in an inner-city MDS/AML cohort S Goel, J Hall, K Pradhan, C Hirsch, B Przychodzen, A Shastri, I Mantzaris, ... Leukemia 30 (8), 1793-1795, 2016 | 35 | 2016 |
| Modest activity of pomalidomide in patients with myelofibrosis and significant anemia N Daver, A Shastri, T Kadia, A Quintas-Cardama, E Jabbour, ... Leukemia research 37 (11), 1440-1444, 2013 | 33 | 2013 |
| Interplay of immunosuppression and immunotherapy among patients with cancer and COVID-19 Z Bakouny, C Labaki, P Grover, J Awosika, S Gulati, CY Hsu, ... JAMA oncology 9 (1), 128-134, 2023 | 29 | 2023 |
| Epidemiology and survival trend of adult T‐cell leukemia/lymphoma in the United States UA Shah, N Shah, B Qiao, A Acuna‐Villaorduna, K Pradhan, ... Cancer 126 (3), 567-574, 2020 | 29 | 2020 |
| A clinical study of tomaralimab (OPN-305), a toll-like receptor 2 (TLR-2) antibody, in heavily pre-treated transfusion dependent patients with lower risk myelodysplastic … G Garcia-Manero, EJ Jabbour, MY Konopleva, NG Daver, G Borthakur, ... Blood 132, 798, 2018 | 29 | 2018 |
| In-hospital outcomes of thrombolysis for acute ischemic stroke in patients with primary brain tumors SB Murthy, Y Moradiya, S Shah, A Shastri, EM Bershad, JI Suarez Journal of clinical neuroscience 22 (3), 474-478, 2015 | 29 | 2015 |
